ArticleAlpha psychiatry2026
Imatinib-Induced Changes in Anxiety-Like Behaviors are Associated With Prefrontal Cortical Metabolic Remodeling in Mice.
Article in Alpha psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anxiety-related symptoms are frequently reported in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. However, the role of TKIs, including imatinib, in development of anxiety remains unclear. The prefrontal cortex (PFC) is closely associated with anxiety-like behaviors, and its metabolic components, particularly lipid- and myelin-related metabolites, are involved in their regulation. Whether imatinib affects brain metabolism remains unknown. This study aimed to evaluate the effects of imatinib on anxiety-like behaviors and to investigate associated metabolic alterations in the PFC. Methods: Anxiety-like behaviors were assessed using a battery of behavioral assays in imatinib-treated mice. PFC tissues from imatinib-treated and control mice were subjected to untargeted metabolomic analysis. Results: Imatinib-treated mice exhibited selective alterations in anxiety-like behaviors. Metabolomic analysis revealed distinct metabolic profiles between the two groups, with significant changes in lipid-related pathways, particularly sphingolipid metabolism. These findings extend the current understanding of the metabolic basis of anxiety-like behaviors and suggest that TKI treatment may influence neuropsychiatric processes through metabolic remodeling of the PFC. Conclusions: This study highlights a potential link between TKI therapy and brain metabolism and provides a framework for understanding the neurobiological basis of anxiety-related effects. These findings may inform future research on the neuropsychiatric consequences of targeted cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.